Kidney Neoplasms Clinical Trial
Official title:
Pilot Study to Develop 3 Tesla MRI for Evaluation of Renal Tumors
The goal of this clinical research study is to find out if "3 Tesla" MRI is as good as CT scan in the evaluation of kidney tumor(s). Objectives: To provide preliminary data to enable subsequent development of an MRI protocol at 3 Tesla for evaluation of renal tumors and their vascular supply, which can be adopted in patients who are unable to undergo CT evaluation.
"3 Tesla" MRI is a new MRI scanner that in theory, can produce better images than currently available MRI scanners. Currently, CT scanning is the main way of evaluating tumors in the kidneys. However, there are some patients who cannot have CT scans (usually, because of allergy to CT contrast medium or kidney damage/failure). It is with these patients that researchers are hoping to use a technique (using MRI) that is as good as CT scanning. As part of your standard of care, your doctor is requesting a CT scan of your kidneys and abdomen. If you take part in this study, you will have a "3 Tesla" MRI scan of your kidneys and abdomen as well, within 15 days following your routine CT. For the "3 Tesla" MRI scan, you will be lying flat on the MRI scanner, and as with a regular scan, you will have a small needle placed in a vein in your arm to inject the contrast dye. A diuretic, Lasix, will be given to help distend the internal tubes in the kidney to help view your kidney better. The MRI scan will take between 1-2 hours to perform. As with regular scans, you may be asked to hold your breath on occasions. If there is a concern about your kidney function, blood (about 1 teaspoon) will be drawn to test your kidney function before you have the MRI. Your participation in the study will be complete at the end of the MRI scan. The routine CT scan will be the main decision making examination. However, if the MRI shows something different and potentially relevant to your care, your referring physician will be informed. This is an investigational study. A total of 45 patients will take part in this study. All will be enrolled at MD Anderson. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00678392 -
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT03129724 -
Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib
|
N/A | |
| Terminated |
NCT01413607 -
The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy
|
Phase 4 | |
| Terminated |
NCT00091611 -
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
|
Phase 1 | |
| Terminated |
NCT02439008 -
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
|
N/A | |
| Completed |
NCT01688999 -
Cabozantinib for Advanced Urothelial Cancer
|
Phase 2 | |
| Recruiting |
NCT05184504 -
Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American
|
||
| Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|
||
| Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
| Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT02543645 -
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
|
Phase 1 | |
| Terminated |
NCT01712685 -
Imaging Studies of Kidney Cancer Using 18F-VM4-037
|
Phase 2 | |
| Terminated |
NCT00816686 -
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer
|
Phase 1 | |
| Completed |
NCT00537056 -
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
|
N/A | |
| Completed |
NCT00076011 -
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT00226980 -
A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
|
Phase 2 | |
| Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
| Recruiting |
NCT03160274 -
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
|
||
| Recruiting |
NCT03062410 -
Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma
|
N/A | |
| Completed |
NCT02924922 -
Assessment of Oncological and Functional Outcomes After Robot Assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy
|
N/A |